Citations

Clear

16280 citation(s) found for "Yu, David".

Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Mendez, Joe , Cohen, Adam L. , Eckenstein, Midori, Jensen, Randy L. , Burt, Lindsay , Salzman, Karen L. , Chamberlain, Marc C. , Hsu, Henry H. , Hutchinson, Marguerite, Mrugała, Maciej M. , Pelayo, Michael, Raizer, Jeffrey J. , Reardon, David A. , Sterba, Michael, Walbert, Tobias , Wong, Eric T. , Zhang, Chao , Colman, Howard , Mendez, Joe S , Reardon, David A , Walbert, Tobias , Colman, Howard , IWAMOTO, FABIO MASSAITI , Ligon, Keith L , Plotkin, Scott R. , Puduvalli, Vinay K. , West, Brian L.

Mayo Clinic

Neuro-Oncology Advances | November 19, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae202 | PMID 39734810 Get It

Abstract Background Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indicate that combining radiation therapy (RT) and pexidartinib reduces radiation resistance. We added pexidartinib to standard-of-care RT/temozolomide (TMZ) in patients with newly diagnosed GBM to assess the therapeutic benefit of altering the tumor microenvironment with pexidartinib. Methods In this open-label, dose-escalation, multicenter, Phase 1b/2 trial, pexidartinib was administered in combination with RT/TMZ followed by adjuvant pexidartinib + TMZ. During Phase 1b, pexidartinib was given 5 or 7 days/week at multiple dosing levels. The primary Phase 1b endpoint was the recommended Phase 2 dose (RP2D). Phase 2 patients received the RP2D with the primary endpoint of median progression-free survival (mPFS). Secondary objectives were median overall survival (mOS), pharmacokinetics, and safety. Results The RP2D of pexidartinib was 800 mg/day for 5 days/week during RT/TMZ, followed by 800 mg/day for 7 days/week with adjuvant TMZ. mPFS was 6.7 months (90% CI: 4.5, 11.5) for the modified intention-to-treat population. The actual mOS was 13.1 months (90% CI: 11.5, 24.5), and the mOS corrected for comparison with matched historical controls was 18.8 months (95% CI: 12.6, 28.0). Conclusions This trial established the RP2D of pexidartinib in combination with RT/TMZ and adjuvant TMZ. Pexidartinib was generally safe and well tolerated. Although the study regimen with pexidartinib was not efficacious, pharmacodynamic studies showed modulation of systemic markers that could lead to alteration of the tumor microenvironment.
Family Socioeconomic Status and Neurodevelopment Among Patients With Dextro-Transposition of the Great Arteries
Cassidy, Adam R. , Rofeberg, Valerie , Bucholz, Emily M. , Bellinger, David C., Wypij, David , Newburger, Jane W.

Mayo Clinic

JAMA Network Open | November 19, 2024 | Volume: 7 | Issue: 11 | Pages: e2445863

10.1001/jamanetworkopen.2024.45863 | PMID 39560944 Get It

Importance Data are limited on the longitudinal implications of socioeconomic status (SES) for neurodevelopmental outcomes among persons with complex congenital heart disease (CHD). Objectives To examine the association of family SES, maternal educational level, and maternal IQ with the neurodevelopment of individuals with dextro-transposition of the great arteries (d-TGA) from age 1 to 16 years and to identify how SES-related disparities change with age. Design, Setting, and Participants This cohort study analyzed data of participants enrolled in the Boston Circulatory Arrest Study, a randomized clinical trial conducted in Boston, Massachusetts, from 1988 to 1992. Participants were infants with d-TGA who underwent arterial switch operation and, after operation, underwent in-person neurodevelopmental status evaluations at ages 1, 4, 8, and 16 years. Analyses were conducted from April 2021 to August 2024. Exposures Mean Hollingshead scores at birth, age 1 year, and age 4 years were used to assign participants to SES tertiles (lowest, middle, or highest). Main Outcomes and Measures Age-appropriate neurodevelopmental outcomes assessed at 4 study time points (ages 1, 4, 8, and 16 years) via in-person administration of a range of well-validated measures. Standardized neurodevelopmental composite scores from each evaluation were derived from principal component analysis and compared across SES tertiles, adjusting for birth and medical characteristics. These scores were used to categorize the sample into latent classes; patient and medical factors for a 3-class model were used to estimate latent class using multinomial regression. Results The sample included 164 patients with d-TGA (123 males [75%]; mean [SD] gestational age at birth, 39.8 [1.2] weeks; 3 with Asian [2%], 6 with Black [4%], 5 with Hispanic [3%], and 146 with White [89%] race and ethnicity) and their mothers (mean [SD] age at birth, 28.5 [5.2] years). Lower SES tertile was associated with worse scores on most individual neurodevelopmental tests and worse neurodevelopmental composite scores at ages 4, 8, and 16 years. For example, mean (SD) neurodevelopmental composite scores at age 4 years were –0.49 [0.83] for lowest, 0.00 [0.81] for middle, and 0.47 [1.10] for highest SES tertile ( F 2 = 15.5; P < .001). When measured at consecutive time points, differences between SES tertiles were of similar magnitude. A latent class analysis produced 2- and 3-class models representing patients with stable (103 [64%] and 85 [53%]), improving (20 [13%]), and declining (57 [36%] and 55 [34%]) neurodevelopmental status. Those experiencing declines in neurodevelopmental status were more likely to have younger maternal age at childbirth (26.6 [5.1] vs 29.6 [4.9] and 29.1 [5.1] years; P = .002), lower maternal IQ (91.0 [14.1] vs 100.1 [11.1] and 96.2 [11.0]; P < .001), and lower SES (35.2 [10.8] vs 40.9 [9.9] and 35.8 [10.1]; P = .003) compared with those with stable or improving status. Conclusions and Relevance This cohort study of individuals with d-TGA found an association between lower family SES and worse neurodevelopmental outcomes in childhood and continuing throughout adolescence as well as greater decline in neurodevelopmental status over time. Effective strategies are needed to improve access to neurodevelopmental monitoring and intervention services for children with CHD from lower socioeconomic backgrounds.
EXCELLENT Registry: A Prospective, Multicenter, Global Registry of Endovascular Stroke Treatment With the EMBOTRAP Device
Nogueira, Raul G. , Andersson, Tommy , Haussen, Diogo C , Yoo, Albert J. , Hanel, Ricardó A. , Zaidat, Osama O. , Hacke, Werner , Fiehler, Jens , Brinjikji, Waleed , Doyle, Karen , Kallmes, David F. , Liebeskind, David S. , Kokoszka, Malgosia A., Inoa, Violiza , Humphries, William, Woodward, Keith, Bozorgchami, Hormozd, Boor, Stephan , Cohen, José E. , Taqi, Muhammad , Budzik, Ronald F. , Hussain, M. Shazam , Estrade, Laurent , Puri, Ajit S., Brekenfeld, Caspar , Siddiqui, Adnan H. , Jovin, Tudor G , Fiehler, Jens , De Meyer, Simon F , Brinjikji, Waleed , Doyle, Karen M , Liebeskind, David S. , Virmani, Renu , Inoa, Violiza , Jabbour, Pascal , Levy, Elad I , Boor, Stephan , Cohen, Jose E , Dashti, Shervin R , Schirmer, Clemens M , Estrade, Laurent , De Leacy, Reade , Chitale, Rohan V , Brekenfeld, Caspar , Siddiqui, Adnan H , Andersson, Tommy , Hanel, Ricardo A , Nogueira, Raul G , Yoo, Albert J , Jovin, Tudor G. , Virmani, Renu , Jabbour, Pascal , François, Olivier , Levy, Elad I. , Schirmer, Clemens M. , Leacy, Reade De , Puri, Ajit S

Mayo Clinic

Stroke | November 19, 2024 | Volume: 55 | Issue: 12 | Pages: 2804-2814

10.1161/strokeaha.124.047324 | PMID 39559856 Get It

BACKGROUND: The EXCELLENT registry aimed to evaluate the effectiveness of the EMBOTRAP Revascularization Device in an all-comer population in a real-world setting, with a focus on the composition of retrieved clots. METHODS: EXCELLENT is a prospective, global registry of patients with acute ischemic stroke treated with EMBOTRAP as the first-line mechanical thrombectomy device conducted at 34 sites (25 sites contributing clot) from September 2018 to March 2021, utilizing core imaging and central histology laboratories blinded to clinical data, independent 90-day modified Rankin Scale assessment and Clinical Events Committee. RESULTS: After screening 3799 patients, a total of 997 subjects (mean age, 70.0±14.2 years; 51.8% women; 19.7% non-White) were included. The first-pass modified Treatment in Cerebral Infarction (mTICI) ≥2b rate was 64.5% (623/966), first-pass mTICI ≥2c was 39.1% (378/966), and final mTICI ≥2b was 94.5% (931/985). A total of 427/912 (46.8%) patients achieved a 90-day modified Rankin Scale of 0 to 2 or ≤baseline. Embolization to a new territory occurred in 0.2% (2/984), and symptomatic intracranial hemorrhage at 24 hours in 1.6% (16/997). The 90-day mortality was 19.1% (175/918). Device- and/or procedure-related serious adverse events occurred in 5.9% (54/912) through 90 days. The mean RBC percentage of retrieved clots was 45.62±21.372. Among patients who achieved mTICI ≥2b with the first pass, 15.7% (52/331) and 9.7% (32/331), respectively, had RBC-poor (<25%) and RBC-rich (>75%) clots. Patients with no clot retrieved in any procedural pass had a lower percentage of hyperdense or susceptibility vessel sign on baseline imaging (58.9% versus 74.7%; P <0.001), pointing to a potential preprocedure indicator of challenging clot. CONCLUSIONS: The EXCELLENT registry informs real-world practices in mechanical thrombectomy and sheds light on the range of clots effectively retrieved by current technology. This is the first report of detailed patient characteristics where mechanical thrombectomy maneuvers failed to remove any clot material. Although the composition of nonretrievable clots cannot be assessed histologically, the results support the notion that no retrieval may be correlated with imaging findings suggesting clots lower in RBC. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03685578.
Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis
Sabik, Joseph F. , Rao, Vivek , Dagenais, François, Moront, Michael G., Patel, Himanshu J. , Oh, Jae K. , Fukuhara, Shinichi , Labrousse, Louis , Günzinger, Ralf, Wu, Tianhua, Investigators, PERIGON, Pettersson, Gosta, Koprivanac, Marijan, Svensson, Lars, Brown, W Morris, Gammie, James, Dawood, Murtaza, Moront, Michael G, Raikar, Goya, Tahirkheli, Naeem, Cannon, Michael, Kress, David, Ribakove, Greg, Patel, Himanshu J, Kerendi, Faraz, Fullerton, David, Baker, Craig, Beaver, Thomas, Ramlawi, Basel, Reardon, Michael J, Aldea, Gabriel, Sundt, Thoralf, Duff, Steven, Steffen, Robert J, Kshettry, Vibhu, Borger, Michael, Takeda, Koji, Adams, David H, Fischbein, Michael, Hagberg, Robert, Ruel, Marc, Rao, Vivek, Dagenais, Francois, Cartier, Raymond, Chu, Michael, Kaufeld, Tim, Shrestha, Malakh, Alfieri, Ottavio, Bensari, Nawel, Holubec, Tomas, Weber, Alberto, Ouda, Ahmed, Falk, Volkmar, Schönhoff, Florian, Carrel, Thierry, Labrousse, Louis, Klautz, Robert J M, Leeuwen, Wouter J van, Kappetein, Ari Pieter, Walther, Thomas, Moritz, Anton, Baig, Kamran, Bapat, Vinayak, Kuhn, Elmar, Wahlers, Thorsten, Kiefer, Philipp, Misfeld, Martin, Günzinger, Ralf, Lange, Rudiger, Chu, Michael , Reardon, Michael J , Patel, Himanshu J , Labrousse, Louis , Ito, Saki , Chu, Michael W A , Reardon, Michael J. , Baig, Kamran M. , Ito, Saki , Klautz, Robert J.M. , Investigators, PERIGON, Pettersson, Gosta, Koprivanac, Marijan, Svensson, Lars, Brown, W Morris, Gammie, James, Dawood, Murtaza, Moront, Michael G, Raikar, Goya, Tahirkheli, Naeem, Cannon, Michael, Kress, David, Ribakove, Greg, Patel, Himanshu J, Kerendi, Faraz, Fullerton, David, Baker, Craig, Beaver, Thomas, Ramlawi, Basel, Reardon, Michael J, Aldea, Gabriel, Sundt, Thoralf, Duff, Steven, Steffen, Robert J, Kshettry, Vibhu, Borger, Michael, Takeda, Koji, Adams, David H, Fischbein, Michael, Hagberg, Robert, Ruel, Marc, Rao, Vivek, Dagenais, Francois, Cartier, Raymond, Chu, Michael, Kaufeld, Tim, Shrestha, Malakh, Alfieri, Ottavio, Bensari, Nawel, Holubec, Tomas, Weber, Alberto, Ouda, Ahmed, Falk, Volkmar, Schönhoff, Florian, Carrel, Thierry, Labrousse, Louis, Klautz, Robert J M, Leeuwen, Wouter J van, Kappetein, Ari Pieter, Walther, Thomas, Moritz, Anton, Baig, Kamran, Bapat, Vinayak, Kuhn, Elmar, Wahlers, Thorsten, Kiefer, Philipp, Misfeld, Martín , Günzinger, Ralf, Lange, Rudiger

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 18, 2024 | Volume: 67 | Issue: 1 | Pages: No page available

10.1093/ejcts/ezae414 | PMID 39565905 Get It

Abstract OBJECTIVES Safety, efficacy and durability are important considerations when selecting a bioprosthesis for aortic valve replacement (AVR). This study assessed 7-year clinical outcomes and haemodynamic performance of the Avalus bioprosthesis. METHODS Patients indicated for surgical AVR were enrolled in this prospective, nonrandomized trial, conducted across 39 sites globally. The primary end-point of this analysis was freedom from surgical explant or percutaneous valve-in-valve reintervention due to structural valve deterioration (SVD) at 7 years of follow-up, determined using Kaplan–Meier (KM) analysis. We also evaluated a composite end-point of SVD and/or severe haemodynamic dysfunction requiring reintervention. Survival, valve-related safety events and haemodynamic performance were assessed. Deaths and safety events were adjudicated by an independent clinical events committee. RESULTS A total of 1132 patients underwent surgical AVR. Mean age was 70 years; 854 patients (75%) were men. The mean STS risk of mortality was 2.0 ± 1.4%, and 659 patients (58%) had a New York Heart Association classification of I/II. One or more concomitant procedures were performed in 577 patients (51%). At 7 years, the Kaplan–Meier rate of freedom from SVD/severe haemodynamic dysfunction requiring reintervention was 1.2% (0.5–2.5%) with no cases adjudicated as SVD. The survival rate was 82.6% (79.5–85.0%). The KM event rate was 5.7% (4.3–7.7%) for reintervention, 6.3% (4.9–8.3%) for endocarditis and 0.4% (0.1–1.1%) for valve thrombosis. Mean aortic gradient, dimensionless velocity index and effective orifice area were 13.8 ± 5.9 mmHg, 0.42 ± 0.09 and 1.99 ± 0.53 cm2, respectively. CONCLUSIONS This analysis demonstrated excellent durability of the Avalus valve with good clinical outcomes and stable haemodynamic performance through 7 years of follow-up.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Desai, Milind Y. , Wolski, Kathy , Owens, Anjali , Geske, Jeffrey B. , Saberi, Sara , Wang, Andrew , Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Naidu, Srihari S. , Smedira, Nicholas G. , Gong, Zhiqun, Mudarris, Lana, Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Investigators, for the VALOR-HCM, Sherrid, Mark , Cremer, Paul C , Lakdawala, Neal K , Tower-Rader, Albree , Naidu, Srihari S , Smedira, Nicholas G , Schaff, Hartzell , Sehnert, Amy J , Nissen, Steven E , Geske, Jeffrey B , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Fermin, David , Schaff, Hartzell V. , Investigators, for the VALOR-HCM

Mayo Clinic

Circulation | November 18, 2024 | Volume: 151 | Issue: 19 | Pages: 1378-1390

10.1161/circulationaha.124.072445 | PMID 39556124 Get It

BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov ; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128. RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction <50% (2 with left ventricular ejection fraction ≤30%; 1 death). Of these, 12 of 15 (80%) continued treatment. New-onset atrial fibrillation occurred in 11 (10.2%) patients (4.55 per 100 patient-years). CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Clinical Evaluation of the NaviNetics Stereotactic System Using Intraoperative Portable Surgical Imaging System in DBS Surgery
Shin, Jee Won , Mandybur, Ian, Hussein, S.H., Klassen, Bryan T. , Gregg, Nick, Miller, Kai J. , Shin, Hojin , Vansickle, David, Lee, Kendall H. , Scheitler, Kristen M. , Sharaf, Basel , Mandybur, Ian, Grewal, Sanjeet S. , Chang, Jin Woo , Oh, Yoonbae

Mayo Clinic

Operative Neurosurgery | November 18, 2024 | Volume: 29 | Issue: 1 | Pages: 93-101

10.1227/ons.0000000000001427 | PMID 39883866 Get It

BACKGROUND AND OBJECTIVES: A typical workflow for deep brain stimulation (DBS) surgery consists of head frame placement, followed by stereotactic computed tomography (CT) or MRI before surgical implantation of the hardware. At some institutions, this workflow is prolonged when the imaging scanner is located far away from the operating room, thereby increasing workflow times by the addition of transport times. Recently, the intraoperative O-arm has been shown to provide accurate image fusion with preoperative CT or MR imaging, suggesting the possibility of obtaining an intraoperative localization scan and postoperative confirmation. In this article, we aim to evaluate the compatibility of the stereotactic frame system with the intraoperative O-arm system regarding lead accuracy and surgical flow. METHODS: A total of 17 patients undergoing DBS surgery for movement disorders were evaluated. One patient underwent both the stereotactic CT and O-arm localization, while 16 patients underwent only intraoperative O-arm localization. Following lead placement, intraoperative O-arm imaging was obtained to evaluate the accuracy of the lead placement. Accuracy was defined as the error measured as the distance from the center of the planned trajectory to the cannula. RESULTS: Less than 0.1 mm difference was found between the O-arm imaging technique and CT image localization of the NaviNetics stereotactic head frame in DBS surgery. Of the 16 patients who underwent the intraoperative O-arm imaging alone, the targets included bilateral ventral intermediate nucleus (16 leads), bilateral globus pallidus internus (4 leads), and subthalamic nucleus (12 leads). The mean ± SD radial error in the probe's eye view was 0.71 ± 0.33 mm for n = 32 leads. No tract hemorrhage was observed. CONCLUSION: Intraoperative O-arm imaging can be used safely and effectively for stereotactic registration and lead placement confirmation with the stereotactic system in both awake and asleep DBS surgery.
Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial
Wixner, Jonas, Adams, David , Polydefkis, Michael , Conceição, Isabel , Dyck, P. James B. , Folkvaljon, Folke, Zhou, Wunan , Chen, Jersey , Viney, Nicholas J. , Kwoh, T. Jesse, Coelho, Teresa , Adams, David , Conceição, Isabel , Gillmore, Julian D , Berk, John L. , Attarian, Shahram , Gillmore, Julian D. , Waddington‐Cruz, Márcia

Mayo Clinic

Amyloid | November 18, 2024 | Volume: 32 | Issue: 1 | Pages: 29-38

10.1080/13506129.2024.2427290 | PMID 39552152 Get It

Circulating miRNA profiles as predictive biomarkers for aneurysm healing following endovascular treatment: a prospective study
Arul, Santhosh , Jassen, Erik, Ayers-Ringler, Jennifer , Şenol, Yiğit Can , Orscelik, Atakan , Ghozy, Sherief , Brinjikji, Waleed , Kallmes, David F. , Kadirvel, Ramanathan , Mereuta, Oana Madalina , Senol, Yigit Can , Orscelik, Atakan , Ghozy, Sherief , Kallmes, David F , Kadirvel, Ram

Mayo Clinic

Interventional Neuroradiology | November 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241298321 | PMID 39552445 Get It

Background Aneurysm treatments are crucial to minimize the rupture risk. The underlying molecular processes mediating cellular remodeling, endothelialization, and aneurysm healing following endovascular treatment are poorly understood. The current study aims to explore circulating miRNA as a treatment and outcome-associated biomarkers in patients undergoing endovascular treatment. Methods Patients undergoing endovascular interventions for unruptured intracranial aneurysms, using either flow diverter placement or coil embolization, were enrolled. Blood samples were collected before the intervention and during a follow-up period between 6 and 18 months. Total mRNA/miRNA was isolated from plasma, followed by RNA-seq analysis. Gene Ontology analysis was used to identify pathways linked to altered miRNA expression. Results Twenty-three patients participated, with 13 (56.5%) undergoing flow diversion and 10 (43.5%) coil embolization. The median follow-up sample collection time was 10.70 months (SEM ± 1.32). No significant differences in angiographic occlusion were noted between intervention groups. Differentially expressed miRNAs were not identified between groups at baseline. However, at follow-up, 39 miRNAs were upregulated and 41 were downregulated, independent of intervention. Notably, three miRNAs (miR-4746-5p, miR-4685-3p, and miR-490-3p) were downregulated in the flow diversion group compared to the coil embolization group. Bioinformatics analysis revealed associations with upregulated fluid shear stress, p53, adherens junction pathways, along with downregulated apoptosis pathways. Conclusions This study suggests that fluid shear stress and apoptosis may influence aneurysm healing or thromboembolic events in flow diverter-treated patients. Further research is warranted to elucidate the functional significance of these findings in treatment outcomes, providing valuable insights for improved patient care in intracranial aneurysm management.
Establishment of a brain tumor consortium of Africa: Advancing collaborative research and advocacy for brain tumors in Africa
Odukoya, Lateef A , Darko, Kwadwo , Zerd, Francis , Ghomsi, Nathalie , Kabare, Gloria , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Kitange, Gaspar J. , Akinjo, Andrea O , Badmos, Kabir, Idowu, Olufemi Emmanuel , Karekezi, Claire , Edrick, Elias, Katasi, Victoria Mwebe , Magambo, Margreth, Magoha, Michael, Ngaiza, Advera , Okemwa, Minda, Osei‐Tutu, Lawrence, Petershie, Bernard, Yevudza, W Elorm , Anunobi, C C , Tiamiyu, Liadi, Gankpé, Gbètoho Fortuné, Heronima, Kashaigili, Higgins, Dominique, Schroeder, Kristin, Totimeh, Teddy , Cheserem, Beverly , Gankpé, Fortuné Gbètoho , Schroeder, Kristin , Jenkins, RB , Karekezi, Claire , Brown, Desmond A., Huse, Jason T. , Balogun, James , Schroeder, Kristin , Zerd, Francis , Odukoya, Lateef A , Darko, Kwadwo , Idowu, Olufemi E , Kamson, David , Bankole, Olufemi , Ekhator, Chukwuyem , Brown, Desmond , LLEWELLYN, HENRY J. , Barrie, Umaru , Nyalundja, Arsène Daniel , Schroeder, Kristin, Etame, Arnold B. , Fonkem, Ekokobe

Mayo Clinic

Neuro-Oncology Advances | November 16, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae198 | PMID 39659834 Get It

Abstract Background Brain tumors represent a significant global health challenge, with rising incidence and mortality impacting individuals worldwide and contributing to cancer-related morbidity and mortality. In Africa, this burden is exacerbated by limited access to advanced diagnostics, treatment options, and multidisciplinary care, compounded by the absence of standardized cancer registration and tumor biobanking. The introduction of molecular diagnostics, as outlined in the 2021 World Health Organization central nervous system (CNS) tumor classification, adds complexity to brain tumor management, particularly in regions with scarce resources. Methods To address these issues, the Brain Tumor Consortium for Africa (BTCA) was established in 2023, bringing together experts to improve CNS tumor diagnosis, patient care, and research. The initial project, conducted via an electronic questionnaire, aimed to assess neuro-oncology capacity across Sub-Saharan Africa. Results The study revealed significant gaps, with a limited number of institutions incorporating molecular subtyping into their diagnostic algorithms. The consortium’s efforts focus on enhancing local data use, informing public policy, and promoting collaboration to advance neuro-oncology practices in Africa. By fostering a network enlisting the expertise of collaborators in the fields of neurosurgery, neurology, neuropathology, anatomic pathology, and medical and radiation oncology, the BTCA seeks to improve brain tumor management through better diagnostics, infrastructure, and policy advocacy. Future directions include expanding molecular diagnostic capabilities, standardizing brain tumor biobanking, enhancing data collection, and advocating for improved brain tumor care in national health agendas. Conclusions The BTCA represents a pioneering model of collaboration and innovation in addressing the unique challenges of brain tumor care in Africa.
Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?
Brunelli, Alessandro , Petersen, René Horsleben , Stiles, Brendon M. , Wigle, Dennis A. , Collaborators, Platz, Joseph , Muesse, Jason , Grenda, Tyler R., Makey, Ian A. , Khandhar, Sandeep J. , Schipper, Paul H., Linsky, Paul L., Liptay, Michael J, Pechet, Taine, White, Abby , Wood, Douglas E. , Brandt, Whitney S. , Martin, Linda D., Patterson, Alec, Seder, Christopher W. , Lanita, Michael, Molena, Daniela , Lee, Jay M. , Healy, David , Decker, G. Anton , Sihoe, Alan , Zairi, Sarra , Dunning, Joel , Raveglia, Federico , Kleontas, Athanasios, Szántó, Zalán , Nosotti, Mario , Hudson, Jessica , Schneiter, Didier, Asadi, Nizar , Aranda, J.M. Botía, Congregado, Miguel , Backhus, Leah, Bertani, Alessandro , Nadal, Sergio Bolufer, Rosso, Lorenzo, Gattás, Gustavo, Augustin, Florian , Milton, Richard , Vannucci, Fernando , Waller, David , Gasparri, Mario, Reddy, Rishindra M. , Schreurs, W. H. , Saftić, Igor, Scarci, Marco, Toker, Seyfi Alper, Welcker, K , Furák, József, Durand, Marion, Hugen, Niek , Joseph, Lula Lukadi, Chiappetta, Marco , Pérez, María Rodríguez, Minasyan, Anna , Filose, Pier Luigi, Elkhayat, Hussein , Wei, Benjamin , Leone, Richard J., Chang, Albert S., Curcio, Carlo, Sparks, Preston, Hagen, Jeffrey A., Baste, Jean Marc , Taylor, Lauren , Xavier, D'journo, Hall, David Jeffrey, Hansen, Henrik Jessen, Leschber, Gunda, Koryllos, Aris , Gandhi, Shilpa , Batgirl, Hasan, Calvin, Ng Sze Hang, Sotiropoulos, Georgios C. , Furrer, Markus , Danjouma, Cheufou, Novoa, Nuria , Cassivi, Stephen D. , Veronesi, Giulia , Hamouri, Shadi , Štupnik, Tomaž , Hall, David J. , Antonoff, Mara B. , Collaborators, Louie, Brian E. , Daddi, Niccolò , Swisher, Stephen G. , Yendamuri, Sai S , Liptay, Michael J, Herrera, Luis, Martin, Linda, Patterson, Alec, Sandri, Alberto , Ruffini, Enrico , Maurizi, Giulio , Kleontas, Athanasios, Depypere, Lieven , Caruana, Edward Joseph , Mitchell, John , Gonfiotti, Alessandro , Pagès, P , Aranda, Jose, Billè, Andrea , Falcoz, Pierre‐Emmanuel , Rosso, Lorenzo , Terra, Ricardo Mingarini , Raemdonck, Dirk Van , Minervini, Fabrizio , Tosi, Davide , Solli, Piergiorgio , Scarci, Marco , Gooseman, Michael , Gossot, Dominique , Álvarez, Antonio , Toker, Seyfi Alper, Aramini, Beatrice , Guerrera, Francesco , Jiménez, Marcelo Fernando , Bölükbas, Servet , Thomas, P. A. , Luzzi, Luca , Aigner, Clemens , Minasyan, Anna, Kim, Young Tae , Pompili, Cecilia , Shargall, Yaron , Fiorelli, Alfonso , Curcio, Carlo, Bilfinger, Thomas V. , Engelhardt, Kathryn Elizabeth , Hall, David Jeffrey, Akopov, Andrey L. , Loos, Erik Robert de , Karamustafaoğlu, Yekta Altemur , Bertolaccini, Luca , Hendriks, Jeroen M. , Scanagatta, Paolo , Prisciandaro, Elena , Gómez-Hernández, María Teresa , Agrafiotis, Apostolos C. , Casiraghi, Monica , Danjouma, Cheufou Housmanou, Mariani, Alessandro Wasum , Antonio, David Gómez de , Bolca, Ciprian Nicolae , Cattaneo, Margherita

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 15, 2024 | Volume: 66 | Issue: 5 | Pages: No page available

10.1093/ejcts/ezae344 | PMID 39545513 Get It